Market capitalization | $7.77b |
Enterprise Value | $6.76b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.98 |
P/S ratio (TTM) P/S ratio | 13.77 |
P/B ratio (TTM) P/B ratio | 6.79 |
Revenue growth (TTM) Revenue growth | 54.31% |
Revenue (TTM) Revenue | $564.53m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
17 Analysts have issued a Intra-Cellular Therapies, Inc. forecast:
17 Analysts have issued a Intra-Cellular Therapies, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 565 565 |
54%
54%
|
|
Gross Profit | 523 523 |
54%
54%
|
|
EBITDA | -112 -112 |
43%
43%
|
EBIT (Operating Income) EBIT | -112 -112 |
43%
43%
|
Net Profit | -84 -84 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
Head office | United States |
CEO | Sharon Mates |
Employees | 610 |
Founded | 2002 |
Website | www.intracellulartherapies.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.